Skip to main content
. Author manuscript; available in PMC: 2018 Dec 18.
Published in final edited form as: Vaccine. 2017 Nov 14;35(51):7121–7126. doi: 10.1016/j.vaccine.2017.10.081

Fig. 4.

Fig. 4

The correlation of DOAc with immunogenicity and protection of GelSite-OAc™. Balb/c mice (n=6) were immunized with GelSite-OAc™ having different DOAc at 2.5 μg/mouse twice, 4 weeks apart. Specific IgG in individual serum samples was measured using the Vi polysaccharide (A) or GelSite-OAc™ (B) as the antigen. Mice were challenged with 100 LD50 of S. Typhi at week 3 following the 2nd immunization. C, % survival; D, Mean body weight. The asterisks indicate significant difference (p<0.05) as compared to the group with 80% DOAc.